HRP20120975T1 - Terapeutska upotreba anti-cs1 antitijela - Google Patents

Terapeutska upotreba anti-cs1 antitijela Download PDF

Info

Publication number
HRP20120975T1
HRP20120975T1 HRP20120975TT HRP20120975T HRP20120975T1 HR P20120975 T1 HRP20120975 T1 HR P20120975T1 HR P20120975T T HRP20120975T T HR P20120975TT HR P20120975 T HRP20120975 T HR P20120975T HR P20120975 T1 HRP20120975 T1 HR P20120975T1
Authority
HR
Croatia
Prior art keywords
seq
antibody
antigen
fragment
binds
Prior art date
Application number
HRP20120975TT
Other languages
English (en)
Croatian (hr)
Inventor
Marna Williams
J. Jun Tso
Nicolas F. Landolfi
Gao Liu
Original Assignee
Abbott Biotherapeutics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbott Biotherapeutics Corp. filed Critical Abbott Biotherapeutics Corp.
Publication of HRP20120975T1 publication Critical patent/HRP20120975T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HRP20120975TT 2004-03-29 2012-11-28 Terapeutska upotreba anti-cs1 antitijela HRP20120975T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies

Publications (1)

Publication Number Publication Date
HRP20120975T1 true HRP20120975T1 (hr) 2013-01-31

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120975TT HRP20120975T1 (hr) 2004-03-29 2012-11-28 Terapeutska upotreba anti-cs1 antitijela

Country Status (8)

Country Link
JP (1) JP4758984B2 (https=)
CY (1) CY1115003T1 (https=)
DK (1) DK2301576T3 (https=)
ES (1) ES2393539T3 (https=)
HR (1) HRP20120975T1 (https=)
IL (1) IL243687A0 (https=)
PT (1) PT2301576E (https=)
SI (1) SI2301576T1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
CA2888803A1 (en) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2911601A (en) * 1999-12-23 2001-07-03 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof

Also Published As

Publication number Publication date
JP4758984B2 (ja) 2011-08-31
HK1099699A1 (en) 2007-08-24
HK1155670A1 (en) 2012-05-25
SI2301576T1 (sl) 2013-02-28
ES2393539T3 (es) 2012-12-26
CY1115003T1 (el) 2016-12-14
PT2301576E (pt) 2012-12-20
IL243687A0 (en) 2016-04-21
JP2007530675A (ja) 2007-11-01
DK2301576T3 (da) 2012-12-10

Similar Documents

Publication Publication Date Title
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20191999T1 (hr) Monoklonska protutijela anti-faktora xi i postupci njihove uporabe
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2020536532A5 (https=)
RU2015144105A (ru) Антитела к гепсидину и их применения
HRP20160494T1 (hr) Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
HRP20221260T1 (hr) Humanizirana i kimerna monoklonska protutijela za cd47
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
RU2016100892A (ru) Антитела против tweakr и их применение
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2009111884A (ru) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
WO2006055809A3 (en) Antibodies against vascular endothelial growth factor receptor-1
RU2010141584A (ru) Антитело против csf-1r
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
HRP20210892T1 (hr) Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv
JP2024024114A5 (https=)
JP2015509960A5 (https=)